PMID- 36401442
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 46
DP  - 2022 Nov 18
TI  - Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for 
      chronic hepatitis B liver fibrosis: A systematic review and meta-analysis.
PG  - e31664
LID - 10.1097/MD.0000000000031664 [doi]
LID - e31664
AB  - BACKGROUND: Meta-analysis was used to evaluate the efficacy of Fufang Biejia 
      Ruangan Tablets in the treatment of chronic hepatitis B (CHB) liver fibrosis. 
      METHODS: Databases, including PubMed, China Knowledge Network (CNKI), China 
      Biomedical Database (CBM), Wan Fang, VIP database, Embase, and Cochrane Library 
      were searched. The time was searched up to May 2022. The participant intervention 
      comparator outcomes of this study were as follows: P, patients with CHB liver 
      fibrosis; I, Fufang Biejia Ruangan Tablets; C, pharmacological placebo; O, the 
      efficacy rate, alanine transaminase (ALT), aspartate aminotransferase (AST), 
      total bilirubin (TBIL), albumin (ALB), procollagen III protein (PIIIP), 
      hyaluronic acid (HA), laminin (LN), collagen C type IV (IV-C), portal vein 
      diameter, spleen thickness and HBV-DNA negative conversion rate. The Cochrane 
      Risk of Bias tool, Begg's test and Egger's test were used to evaluate the 
      methodological quality of eligible studies. A randomized controlled trial of 
      Fufang Biejia Ruangan Tablets was used to treat CHB liver fibrosis. Three 
      reviewers independently selected trials, extracted data, cross-checked, and 
      performed methodological quality assessments. Data analysis was completed by 
      Review Manager 5.3. RESULTS: Twenty-six studies with 2717 patients were included 
      in the meta-analysis. The meta-analysis showed that Fufang Biejia Ruangan Tablets 
      was effective by increasing the efficacy. Fufang Biejia Ruangan Tablets was more 
      efficient in improving ALT, AST, TBIL, ALB, PIIIP, HA, LN, IV-C, portal vein 
      diameter, spleen thickness, and HBV-DNA negative conversion rate with no serious 
      adverse reactions. CONCLUSION: It was shown that Fufang Biejia Ruangan Tablets 
      can effectively improve liver function and relieve liver fibrosis, but future 
      research should focus on rigorously designed, multicenter, and large randomized 
      controlled trials.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Meng, Xiangbo
AU  - Meng X
AUID- ORCID: 0000-0001-6131-2807
AD  - School of Basic Medical Sciences, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Pan, Zhengqi
AU  - Pan Z
AD  - Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, Sichuan Province, China.
FAU - Zhao, Jiawei
AU  - Zhao J
AD  - Hubei Provincial Collaborative Innovation Center of Preventive Treatment by 
      Acupuncture and Moxibustion, Hubei University of Chinese Medicine, Wuhan, Hubei 
      Province, China.
FAU - Feng, Quansheng
AU  - Feng Q
AD  - School of Basic Medical Sciences, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (biejia ruangan)
RN  - 0 (DNA, Viral)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - 0 (Tablets)
RN  - 0 (Adjuvants, Pharmaceutic)
SB  - IM
MH  - Humans
MH  - *Hepatitis B, Chronic/drug therapy
MH  - DNA, Viral
MH  - Liver Cirrhosis/drug therapy
MH  - Alanine Transaminase
MH  - Tablets
MH  - Adjuvants, Pharmaceutic/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Multicenter Studies as Topic
PMC - PMC9678545
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/11/20 06:00
MHDA- 2022/11/23 06:00
PMCR- 2022/11/18
CRDT- 2022/11/19 01:04
PHST- 2022/11/19 01:04 [entrez]
PHST- 2022/11/20 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 00005792-202211180-00082 [pii]
AID - 10.1097/MD.0000000000031664 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Nov 18;101(46):e31664. doi: 
      10.1097/MD.0000000000031664.